Clinical Trial Update: Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy [Phase 2]

View source ↗

Summary

This update covers a Phase 2 trial of bortezomib in patients with diffuse large B-cell lymphoma that is refractory to chemotherapy. The study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED